Ann: Resmed to Announce Third Quarter 2015 Results, page-5

I certainly missed the boat here last year when it dropped to 4 80 - I see massive upside here, even at this lofty price- the health sector will and has continually outperformed. The aud exchange rate is highly favorable to rmd and I also expect strong results.. I will be taking my first position next week hopeful for a drop.

Credit suisse also has a 10.7 valuation target

Trial Could Offer Big Boost for ResMed, Says Credit Suisse -- Market Talk

| Page last updated at 10 04 2015 09:07am AEST



2307 GMT [Dow Jones]--As it stands, ResMed's (RMD.AU) shares don't appear to factor in any material contribution from sales of adaptive servo-ventilation, used to treat sleep apnoea, Credit Suisse says. But a prospective study could be particularly influential in driving clinical adoption and a further rerating in RMD shares, the brokerage argues. It estimates the target market for ASV use is large, and could add as much as A$2/share to RMD's valuation. Already two meta-analyses have shown positive results from ASV use in heart-failure patients with periodic breathing. Results of the prospective trial are due by early 2016. Credit Suisse has an outperform recommendation and A$10.70/share target. RMD was last at A$9.51. ([email protected]; Twitter: @RobbMStewart)